Page last updated: 2024-11-06

propisomide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

propisomide: RN from Toxline; RN not in Chemline 8/85; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65847
CHEMBL ID141837
SCHEMBL ID1649694
MeSH IDM0133332

Synonyms (33)

Synonym
penticainide
me-3202
cm-7857
pentisomide
pentisomide [inn]
pentisomida [inn-spanish]
pentisomidum [inn-latin]
propisomide
cm 7857
me 3202
CHEMBL141837
2-[2-[di(propan-2-yl)amino]ethyl]-4-methyl-2-pyridin-2-ylpentanamide
78833-03-1
pentisomidum
alpha-(2-(diisopropylamino)ethyl)-alpha-isobutylpyridine-2-acetamide
pentisomida
unii-506t8ktw5q
506t8ktw5q ,
einecs 278-989-5
FT-0673608
pentisomide [mart.]
pentisomide [who-dd]
pentisomide [mi]
2-pyridineacetamide, .alpha.-(2-(bis(1-methylethyl)amino)ethyl)-.alpha.-(2-methylpropyl)-
(+/-)-.alpha.-(2-(diisopropylamino)ethyl)-.alpha.-isobutyl-2-pyridineacetamide
pentisomide [jan]
SCHEMBL1649694
alpha-[2-(diisopropylamino)ethyl]-alpha-isobutylpyridine-2-acetamide
AKOS030530978
cm 7857; me 3202; penticainide; pentisomide
DTXSID40869274
Q27260771
2-[[2-(diisopropylamino)ethyl]-4-methyl]-2-(2-pyridyl)pentanamide

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Mean AUC was larger and terminal elimination half-life longer in the elderly subjects, due to a decrease in total plasma clearance of pentisomide in the elderly."( The effect of age on the pharmacokinetics of pentisomide.
Caffrey, E; Darragh, A; Holt, DW; Howse, NL; Johnston, A; Jones, RW; Walker, S, 1991
)
0.28
" Its electrophysiological effects and pharmacokinetic properties were studied in 28 patients undergoing endocavitary exploration for paroxysmal supraventricular tachycardia (10 cases), WPW syndrome involving an accessory pathway (5 cases), and unexplained dizziness (13 cases)."( Electrophysiologic effects and pharmacokinetics of intravenous penticainide (CM 7857).
Aliot, E; Gagnol, JP; Gilgenkrantz, JM; Khalife, K; Munoz, A; Necciari, J, 1987
)
0.27
" The pharmacokinetic parameters of penticainide including Cmax, tmax, AUC and t1/2 were not significantly altered in the presence of food."( Influence of food and body weight on the pharmacokinetics of penticainide.
Bannwarth, B; Berdaï, D; Demotes-Mainard, F; Montels, R; Necciari, J; Philip, F; Vinçon, G, 1994
)
0.29

Dosage Studied

ExcerptRelevanceReference
" Dosage reduction, or a reduced frequency of dosing of pentisomide would be necessary in the elderly or those with impaired renal function."( The effect of age on the pharmacokinetics of pentisomide.
Caffrey, E; Darragh, A; Holt, DW; Howse, NL; Johnston, A; Jones, RW; Walker, S, 1991
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID57156Antiarrhythmic potential in conscious dogs; value ranges from +120 to +3801983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Synthesis and antiarrhythmic activity of new [(dialkylamino)alkyl]pyridylacetamides.
AID63097Intracardiac conduction in anesthetized dogs, measured as HV; HV being the conduction time in specific intraventricular tissue value ranges from +20 to +301983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Synthesis and antiarrhythmic activity of new [(dialkylamino)alkyl]pyridylacetamides.
AID63111Intracardiac conduction in anesthetized dogs, measured as SH; SH being the atrial His bundle conduction time value ranges from +15 to +351983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Synthesis and antiarrhythmic activity of new [(dialkylamino)alkyl]pyridylacetamides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (39)

TimeframeStudies, This Drug (%)All Drugs %
pre-199017 (43.59)18.7374
1990's21 (53.85)18.2507
2000's0 (0.00)29.6817
2010's1 (2.56)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.61 (24.57)
Research Supply Index3.76 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (5.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other38 (95.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]